$15.17
0.00% yesterday
Nasdaq, Nov 27, 01:24 am CET
ISIN
US71722W1071
Symbol
PHAT

Phathom Pharmaceuticals Inc Stock price

$15.17
+1.36 9.85% 1M
+11.15 277.36% 6M
+7.05 86.82% YTD
+6.20 69.12% 1Y
+5.97 64.89% 3Y
-27.49 64.44% 5Y
-9.43 38.33% 10Y
-9.43 38.33% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.24 1.61%
ISIN
US71722W1071
Symbol
PHAT
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.5b
Net debt
$445.3m
Cash
$135.2m
Shares outstanding
71.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.3 | 6.1
EV/Sales
10.4 | 8.7
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-67.0%
Return on Equity
131.8%
ROCE
-145.1%
ROIC
-
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$147.2m | $175.9m
EBITDA
$-212.8m | $-164.9m
EBIT
$-213.5m | $-187.0m
Net Income
$-274.6m | $-233.7m
Free Cash Flow
$-225.4m
Growth (TTM | estimate)
Revenue
460.3% | 218.4%
EBITDA
25.9% | 40.4%
EBIT
25.9% | 32.6%
Net Income
19.1% | 30.1%
Free Cash Flow
9.0%
Margin (TTM | estimate)
Gross
87.3%
EBITDA
-144.6% | -93.7%
EBIT
-145.0%
Net
-186.5% | -132.9%
Free Cash Flow
-153.1%
More
EPS
$-3.7
FCF per Share
$-3.2
Short interest
30.3%
Employees
427
Rev per Employee
$130.0k
Show more

Is Phathom Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Phathom Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Phathom Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
147 147
460% 460%
100%
- Direct Costs 19 19
333% 333%
13%
128 128
485% 485%
87%
- Selling and Administrative Expenses 308 308
14% 14%
209%
- Research and Development Expense 34 34
13% 13%
23%
-213 -213
26% 26%
-145%
- Depreciation and Amortization 0.70 0.70
11% 11%
0%
EBIT (Operating Income) EBIT -213 -213
26% 26%
-145%
Net Profit -275 -275
19% 19%
-187%

In millions USD.

Don't miss a Thing! We will send you all news about Phathom Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Phathom Pharmaceuticals Inc Stock News

Positive
Seeking Alpha
7 days ago
Following Phathom's excellent financial results for Q3, its average price target rose to $23.13, which implies an upside of about 58.8% from its current stock price. Phathom Pharmaceuticals raised its full-year 2025 revenue guidance from $165-$175 million to $170-$175 million. The main reason why vonoprazan franchise sales grew by 201% year-on-year to $49.5 million is its superior efficacy comp...
Neutral
GlobeNewsWire
24 days ago
First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today anno...
Neutral
GlobeNewsWire
25 days ago
FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare I...
More Phathom Pharmaceuticals Inc News

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Head office United States
CEO Steven Basta
Employees 427
Founded 2018
Website www.phathompharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today